EPO906 in Carcinoid and Other Neuroendocrine Tumors

• ClinicalTrials.gov Identifier: NCT00050349
• Recruitment Status: Completed
• First Posted: December 5, 2002
• Last Update Posted: March 1, 2017
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.

Condition or disease	Intervention/treatment	Phase
Carcinoid; Neuroendocrine Tumors	Drug: EPO906 epothilone B	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 33 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
• Study Start Date: July 2002
• Actual Primary Completion Date: April 2007
• Actual Study Completion Date: April 2007

Arms and Interventions

Arm	Intervention/treatment
Experimental: EPO906	Drug: EPO906 epothilone B; Other Name: patupilone

Outcome Measures

Primary Outcome Measures :

1. Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: every 12 weeks ]

Secondary Outcome Measures :

1. Time to progression [ Time Frame: until documented disease progression, death or date of follow up ]
2. Overall survival [ Time Frame: after treatment, every 3 months (maximum of 12 months) ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy
• The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)
• Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry
• Must have a life expectancy of greater than three (3) months
• Karnofsky Performance Status > 60
• Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)

Exclusion Criteria:

• Patients with symptomatic CNS metastases or leptomeningeal involvement
• Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.
• Patients with bone metastases as the only site(s) of measurable disease
• Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)
• Patients who have been previously treated with radioactive directed therapies
• Patients who have been previously treated with epothilone
• Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1
• Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports
• Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ
• Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae
• Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
• HIV+ patients
• Pregnant or lactating females.

Contacts and Locations

Locations

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

United States, Iowa

University of Iowa Health Care

Iowa City, Iowa, United States, 52242-1091

United States, Louisiana

LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)

New Orleans, Louisiana, United States, 70115

United States, New York

Weill Medical College of Cornell Univ.

New York, New York, United States, 10021

United States, Oregon

Oregon Health Sciences University

Portland, Oregon, United States, 97201

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT00050349
• Other Study ID Numbers: CEPO906A2212
• First Posted: December 5, 2002
• Last Update Posted: March 1, 2017
• Last Verified: March 2013

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

cancer; tumor; tumour; neoplasm; carcinoma; carcinoid; neuroendocrine; Islet cell; Gastrinoma; VIPoma; metastatic; intravenous; epothilone

Additional relevant MeSH terms:

Neuroendocrine Tumors; Carcinoid Tumor; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Epothilones; Epothilone B; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents